Neoadjuvant Nivolumab and Ipilimumab for Resectable Stage III Melanoma: The New Standard of Care?
Ann Surg Oncol
.
2024 Dec 29.
doi: 10.1245/s10434-024-16807-3.
Online ahead of print.
Authors
John T Miura
1
,
Giorgos C Karakousis
2
Affiliations
1
Division of Endocrine and Oncologic Surgery, Hospital of the University of Pennsylvania, Philadelphia, PA, USA.
2
Division of Endocrine and Oncologic Surgery, Hospital of the University of Pennsylvania, Philadelphia, PA, USA. giorgos.karakousis@uphs.upenn.edu.
PMID:
39739267
DOI:
10.1245/s10434-024-16807-3
No abstract available
Publication types
Editorial